论文部分内容阅读
目的:汉防己甲素(Tet)为中药粉防己根的提取物。本研究的目的为评价其抗肝纤维作用。方法:用40％CCl_41.2ml/kg体重皮下注射,2次/周,共12周,诱发SD大鼠肝纤维化。于初次注射开始,用Tet(治疗组)或盐水(对照组)灌胃,隔日1次共12周。分别于4、8、12、14周处死动物测定血清Ⅲ型前胶原(PCⅢ)、肝及血清透明质酸(HA)、胶原、储脂细胞(FSC)及其细胞器。结果:Tet可使血清PCⅢ、HA及肝HA降低,肝内胶原沉积减少。治疗结束时,血清PCⅢ为61.8±21.0ug/L,而对照组为270.2±46.1ug/L(P<0.01);血清HA分别为204.0±70.8ug/L与565.2±161.9ug/L(P<0.01);肝组织HA为86.9±15.3ug/g与186.5±46.2ug/g(P<0.01)。FSC及其内织网与线粒体受抑。结论:我们的实验结果显示Tet能抑制肝内胶原的沉积,可用于治疗慢性肝病之肝纤维化。
Objective: Tetrandrine (Tet) is an anti-rhizome extract of traditional Chinese medicine. The purpose of this study was to evaluate its anti-hepatic fibrosis effect. Methods: Liver fibrosis was induced in SD rats by subcutaneous injection with 40% CCl_ (41.2 ml / kg body weight) twice a week for 12 weeks. At the beginning of the first injection, gavage was performed with either Tet (treatment group) or saline (control group) once a day for 12 weeks. The animals were sacrificed at 4, 8, 12 and 14 weeks for the determination of serum PCⅢ, liver and serum HA, collagen, fat-storing cells (FSC) and organelles. Results: Tet could reduce serum PCⅢ, HA and liver HA, and reduce hepatic collagen deposition. At the end of treatment, the serum PCⅢ was 61.8 ± 21.0 ug / L, while the control group was 270.2 ± 46.1 ug / L (P <0.01). The serum HA levels were 204.0 ± 70.8 ug / L and 565.2 ± 161.9 ug / L, respectively 0.01). The liver tissue HA was 86.9 ± 15.3 ug / g and 186.5 ± 46.2 ug / g (P <0.01). FSC and its internal network and mitochondria suppressed. CONCLUSIONS: Our results show that Tet inhibits intrahepatic collagen deposition and can be used to treat liver fibrosis in chronic liver disease.